EBC-46
Drugs injected directly into tumours operate under different regulatory logic than systemic therapies. Here is how EBC-46 is navigating — and reshaping — that framework.
EBC-46
From a post-sepsis patient whose doctor attributed blood-clot resolution to blushwood extract, to a stage 4 cancer case with positive scans — these verified reports demand formal scientific investigation.
EBC-46
The Blushwood tree grows wild only in north Queensland's rainforest, but controlled cultivation has proven viable across Australia and Asia — opening the door to scalable, sustainable supply of tigilanol tiglate.
EBC-46
The first-in-human Phase I trial of tigilanol tiglate demonstrated localised anti-tumour responses with a clean systemic safety profile — a result that immediately distinguished EBC-46 from prior PKC-targeting drugs.
EBC-46
Tigilanol tiglate activates PKC-delta by mimicking the diacylglycerol second messenger, triggering simultaneous vascular disruption, immune cascade, and cancer-cell apoptosis within the tumour.
EBC-46
The FDA's full approval of Stelfonta validated tigilanol tiglate's PKC-activation mechanism for the first time, creating regulatory precedent that directly accelerates human oncology trials.
EBC-46
Tigilanol tiglate is just one compound in the Blushwood berry — the full phytochemical profile of Fontainea picrosperma remains largely uncharacterised and scientifically fascinating.
EBC-46
When doctors look up blushwood extract after seeing unexplained improvements in their patients' blood work, these are not casual testimonials — they are clinical signals worth investigating.
EBC-46
Modern EBC-46 trials are incorporating biomarker endpoints that capture immune activation, vascular disruption, and tissue remodelling — painting a richer picture than tumour size alone.
EBC-46
PKC-delta and PKC-epsilon isoforms play opposing roles in mitochondrial function — EBC-46's selective activation may reshape cellular energy production beyond tumour destruction.
EBC-46
Regulatory frameworks for compassionate use and expanded access could allow tigilanol tiglate to reach patients with unmet needs well before Phase III completion.
EBC-46
After a year or more of daily blushwood extract use, a cohort of verified buyers report sustained reductions in inflammation, improved energy, and unexpected clinical observations their doctors found difficult to explain.